Skip to main content
. 2014 Jun 10;36(10):605–614. doi: 10.1093/eurheartj/ehu218

Table 3.

Safety outcomes, subgroup analyses

  All studies
Alteplase
Tenecteplase
Other thrombolytics
Group difference
OR (95% CI) P-value I2 (%) OR (95% CI) OR (95% CI) OR (95% CI) P-value
Major bleeding 2.91 (1.95 to 4.36) <0.001 25 1.07 (0.43 to 2.62) 5.02 (2.72 to 9.26) 2.16 (1.03 to 4.54) 0.02
Fatal/intracranial haemorrhage 3.18 (1.25 to 8.11) 0.008 0 1.09 (0.27 to 4.40) 7.32 (1.64 to 32.63) NA 0.07